Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

Andrew Witty — who became UnitedHealth Group’s CEO in 2021 — is stepping down from the top post due to personal reasons after ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

GlaxoSmithKline Pharmaceuticals, the Indian arm of UK-based GSK, reported a 35% year-on-year jump in consolidated net profit ...

GSK’s share price has fallen significantly in the past 12 months, but this could mean it looks a major bargain now, ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...